Lytix Biopharma ASA (OSL:LYTIX)
Norway · Delayed Price · Currency is NOK 8.58
+0.18 (2.14%)
Sep 14, 2026, 12:19 PM CET
Lytix Biopharma ASA Cash Flow Statement
Financials in millions NOK. Fiscal year is January - December.
Millions NOK. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -94.62 | -59.98 | -94.27 | -87.9 | -56.07 | -48.08 |
Depreciation & Amortization | 1 | 1 | 0.92 | 0.96 | 0.92 | 0.45 |
Stock-Based Compensation | 14.47 | 13.84 | 0.88 | 4.18 | 1.38 | 4.05 |
Other Operating Activities | -2.34 | -2.32 | -1.5 | -2.35 | -1.35 | -0.13 |
Change in Accounts Receivable | -0.02 | 6.03 | -0.34 | -6.04 | -1.06 | -1.51 |
Change in Accounts Payable | -5.5 | -18.43 | 23.94 | -4.83 | 3.55 | 0.61 |
Operating Cash Flow | -87 | -59.85 | -70.37 | -95.97 | -52.63 | -44.61 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | - | - | -0.05 | -0.15 | - |
Investment in Securities | -2.31 | -61.76 | 23.18 | 27.42 | -50.61 | - |
Other Investing Activities | 2.34 | 2.33 | 1.51 | 2.35 | 1.41 | 0.14 |
Investing Cash Flow | 0.03 | -59.43 | 24.69 | 29.73 | -49.36 | 0.14 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Repaid | - | -0.9 | -0.85 | -0.94 | -0.83 | -0.42 |
Lease Payments | -0.95 | -0.9 | -0.85 | -0.94 | -0.83 | -0.42 |
Net Debt Issued (Repaid) | -0.95 | -0.9 | -0.85 | -0.94 | -0.83 | -0.42 |
Issuance of Common Stock | 77.74 | - | 161.3 | - | 0.13 | 225.21 |
Other Financing Activities | -1 | -0.01 | -11.34 | -0 | -0.06 | -11.49 |
Financing Cash Flow | 75.79 | -0.91 | 149.11 | -0.94 | -0.75 | 213.3 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Miscellaneous Cash Flow Adjustments | - | 0 | - | - | - | -0 |
Net Cash Flow | -11.19 | -120.19 | 103.43 | -67.19 | -102.73 | 168.83 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -87 | -59.85 | -70.37 | -96.02 | -52.78 | -44.61 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | - | -632.05% | -2405.86% | -478.47% | -231.04% |
Free Cash Flow Per Share | -1.24 | -0.88 | -1.30 | -2.40 | -1.33 | -1.34 |
Levered Free Cash Flow | -52.06 | -37.7 | -34.62 | -66.3 | -36.49 | -26.43 |
Unlevered Free Cash Flow | -51.96 | -37.57 | -34.54 | -66.27 | -36.4 | -26.39 |
Free Cash Flow After Leases | -87.95 | -60.75 | -71.22 | -96.96 | -53.61 | -45.03 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0 | 0.01 | 0.01 | 0 | 0.06 | 0 |
Change in Working Capital | -5.51 | -12.39 | 23.6 | -10.87 | 2.5 | -0.9 |